Pharmaceuticals

PKU HEALTHCARE

PKU Healthcare released FY2025 Annual Earnings on April 27 After-Market (BJT), with actual revenue of CNY 1.482 B and actual EPS of CNY 0.1391

PKU Healthcare released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 215.17 M, actual EPS CNY 0.0453

PKU HEALTHCARE released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 251.18 M, actual EPS CNY -0.089

PKU Healthcare FY2026 Q1 Earnings Release on April 28 After-Market BJT

PKU Healthcare FY2025 Annual Earnings Release on April 28, 2026 After-Market BJT

PKU Healthcare released FY2025 9 Months Earnings on October 30 After-Market BJT, actual revenue CNY 1.231 B, actual EPS CNY 0.2281

PKU Healthcare released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue CNY 273.88 M, actual EPS CNY 0.0598

PKU Healthcare FY2025 Q3 Earnings Release on October 31 After-Market BJT

PKU Healthcare released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 454.95 M, actual EPS CNY 0.0916

PKU HEALTHCARE released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 957.31 M, actual EPS CNY 0.1682

PKU HEALTHCARE FY2025 Semi-Annual Earning Release on August 22, 2025 (BJT)

New Controlling Shareholder Xu Xiren Completes Management Shake-up at North University of China Pharmaceutical

BeiDaMedicine's ESG Rating Upgraded to CC

North China Pharmaceutical Invests 5 Million RMB to Set Up a Medical Charity Foundation

North China Pharmaceutical's subsidiary Xinyoushi to engage in securities investment

Beida Pharmaceutical and Yunnan Jianzhijia Reach Strategic Cooperation

North China Pharmaceutical Responds to Shareholder Reduction Concerns

North China Pharmaceutical Q1 2025 Revenue Growth

PKU Healthcare released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 525.68 M, actual EPS CNY 0.0127

PKU Healthcare released FY2025 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 502.36 M, actual EPS CNY 0.0766

301017

600488

301584

000788

301408

600594

603222

600829

301015

603122

China's A-share pharmaceutical industry chain continues to strengthen, with Chimin and CMC hitting the daily limit, following TJPC, YIBAI PHARMACEUTICAL, and PKU HEALTHCARE also hitting the daily limit. Previously, Huaren Health, Baheal Medical, SYPM, INNOSTIC, and HRPC, among other stocks, rose more than 5%

Wallstreetcn

SYPM

TJPC

C&D INNOSTIC

Huaren Health

YIBAI PHARMACEUTICAL

Chimin

HRPC

Baheal Medical

000952

605188

601116

The A-shares closed today with the ChiNext Index opening low and rising over 2%, while the consumer sector strengthened towards the end of trading. The Shanghai Composite Index fluctuated within a narrow range throughout the day, closing down 0.15%; the Shenzhen Component Index rose 1.02%; the ChiNext Index increased by 2.14%. Pharmaceutical stocks were strong, with GUANGJI PHARMA and PKU HEALTHCARE hitting the daily limit. CPO and other computing hardware stocks performed well, with Zhongji Xuchuang soaring over 10%. The consumer sector surged towards the end, with GUOGUANG CHAINS and Sanjiang Shopping Club hitting the daily limit. The military industry sector collectively adjusted, with Jiuzhiyang and Jianglong Shipbuilding dropping over 10%. Most individual stocks fell rather than rose, with over 3,500 stocks in the Shanghai, Shenzhen, and Beijing markets showing losses, and the trading volume nearing 1.8 trillion

GUANGJI PHARMA

GUOGUANG CHAINS

Sanjiang Shopping Club

A-shares closing: The ChiNext index opened lower but rose over 2%, with the consumer sector strengthening in the closing minutes

According to the Zhitong Finance APP, PKU HEALTHCARE released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.231 billion yuan, a year-on-year decrease of 19.76%. The net profit attributable to shareholders of the listed company was 136 million yuan, a year-on-year increase of 4.31%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 126 million yuan, a year-on-year decrease of 2.66%. The basic earnings per share were 0.2282 yuan

Zhitong

PKU HEALTHCARE released its performance for the first three quarters, with a net profit attributable to the parent company of 136 million yuan, an increase of 4.31%

According to the Zhitong Finance APP, PKU HEALTHCARE announced that the company recently received a notification from relevant authorities, informing that the company's chairman and president Xu Xiren has been criminally detained and is currently cooperating with the investigation by relevant departments, making it temporarily impossible for him to perform his duties normally. At present, the company has made proper arrangements for related work, the company's control has not changed, the board of directors is operating normally, and the company's financial and production management situation is normal

PKU HEALTHCARE: Chairman and President Xu Xiren has been criminally detained

PKU HEALTHCARE has obtained the drug registration certificate for Apremilast tablets issued by the National Medical Products Administration, which includes specifications of 10mg and 30mg. Apremilast is a small molecule inhibitor targeting PDE4, primarily used for the treatment of moderate to severe plaque psoriasis, with advantages such as rapid onset, clear efficacy, and high safety

PKU HEALTHCARE has obtained the drug registration certificate for Apremilast Tablets

PKU HEALTHCARE Co., Ltd. announced that its wholly-owned subsidiary "Beijing Beiyi Pharmaceutical Co., Ltd." has been renamed to "Beijing New Advantage Pharmaceutical Commercial Co., Ltd." The legal representative has changed from Yuan Pingdong to Cheng Hong, and the industrial and commercial change registration has been completed, obtaining a new business license. The new company has a registered capital of 100 million yuan, established on June 10, 1998, and its business scope includes pharmaceutical wholesale and medical device sales, among others

PKU HEALTHCARE's wholly-owned subsidiary has been renamed, changed its legal representative, and completed industrial and commercial registration

According to the announcement from PKU HEALTHCARE, the shareholder Beijing Medical Management Co., Ltd. (hereinafter referred to as "Beijing Medical") plans to reduce its holdings of the company's shares by no more than 17.8796 million shares through centralized bidding and block trading within three months after 15 trading days from the date of this announcement (i.e., from October 14, 2025, to January 11, 2026), accounting for 3% of the company's total share capital

PKU HEALTHCARE plans to reduce its holdings by no more than 3% of its shares

PKU HEALTHCARE announced that in the first half of 2025, operating revenue was 957 million yuan, a year-on-year decrease of 5.04%. Net profit was 100 million yuan, a year-on-year increase of 15.51%

PKU HEALTHCARE: Net profit of 100 million yuan in the first half of 2025, a year-on-year increase of 15.51%

PKU HEALTHCARE(000788.SZ)